OKUR OnKure Therapeutics, Inc.
XNAS 3.12 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
OKUR
$3.12
—
What changed
Recent filings, trades and movesKey stats
$3.12
- 52-Week Range
- $2.01 – $5.38
- YTD
- +5.41%
- Straddle Price
- $1.82
- P/C Vol Ratio
- 0.40
- Market Cap
- $0.1B
- Open
- $2.88
- Day Range
- $2.76 – $3.21
- Volume
- 814,191
- Prev Close
- $2.87
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.11 |
| Cost of Equity (CAPM) | 11.01% (VRP-adj) |
| WACC | 11.36% |
| Volatility Risk Premium | +143.2pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.0B |
| Return on Equity (TTM) | -34.1% |
| Book / Price | 120.5% — banking bias active (P/B is primary) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $2.78 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $2.46 |
| Bollinger Width / SMA20 | 30.3% (drives anchor stability) |
| Net Debt | $-0.2B |
| Market Cap | $0B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$13.32
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 42.2× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 21.2× · 3 peers |
| Peer P/B | $13.32 | 100% | median 3.9× · 3 peers |
| Peer P/S | n/a | 0% | median 4.1× · 3 peers |
| Market Anchor (SMA50) | $2.78 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 45
- List Date
- 2024-10-07
- CIK
- 0001637715
- Last Earnings
- Nov 4 after close · −2.7% vs ±105.2% expected
- Headquarters
- Boulder, CO
- Homepage
- https://www.onkuretherapeutics.com
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | -27.82% | -10.81% | -19.32% |
| Feb | -- | -13.92% | 2.65% | -5.63% |
| Mar | -- | -10.97% | 46.29% | 17.66% |
| Apr | -- | -41.55% | 29.48% | -6.03% |
| May | -- | 1.20% | -11.21% | -5.01% |
| Jun | -- | -9.81% | 8.57% | -0.62% |
| Jul | -- | -7.92% | -14.83% | -11.38% |
| Aug | -- | 25.00% | -9.70% | 7.65% |
| Sep | -- | -0.72% | -23.46% | -12.09% |
| Oct | -6.17% | 26.97% | 3.15% | 7.98% |
| Nov | -5.34% | -7.95% | 23.17%* | 3.29% |
| Dec | -42.47% | 2.11% | -- | -20.18% |
| Total | -48.90% | -59.76% | 25.03% | -27.88% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $2.50
SMA 50: $2.77
SMA 200: $3.60
Current: $3.19
EMA 12: $2.68
EMA 26: $2.64
MACD: 0.0314 | Signal: 0.0888
BEARISH
ADX (14): 15.94
RANGE
+DI: 27.84
−DI: 16.04
Momentum Oscillators
RSI (14): 68.43
NEUTRAL
Stoch %K: 89.23
Stoch %D: 82.44
Williams %R: -2.08
Volume & Volatility
BB Upper: $2.99
BB Lower: $2.01
OVERBOUGHT
OBV: -1,851,309
Vol SMA 20: 384,590
Vol ROC: 215.47%
ATR: $0.25
True Range: $0.45
HV 20: 87.0%
HV 30: 83.9%
HV 60: 66.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-11T00:00:00 – 2026-11-09T00:00:00
AI Analysis
Written before OKUR’s Nov 4 earnings report, so it doesn’t reflect the results.
Here is my response:
LLM Stock Analysis Report: OKUR
Executive Summary
Overall Assessment: BEARISH (confidence level: 6/10)
Key Drivers and Primary Risks: High volatility, negative MACD signal, oversold RSI, and recent news headlines suggesting a cautious tone.
Investment Thesis: OKUR is experiencing a period of high volatility, which may lead to further price fluctuations. The recent positive news headlines are not enough to overcome the bearish technical signals and high risk profile.
Recent News Sentiment Impact: Positive sentiment from recent news headlines has had a limited impact on the stock's price movement, as the overall market narrative is still cautious.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): BEARISH
- Medium-term (1-3 months): NEUTRAL
- Long-term (3-12 months): BULLISH
Support/Resistance Levels: Key price levels from moving averages and technical patterns: + SMA 20: $3.72 (resistance) + EMA 12: $3.50 (support)
Momentum Signals:
- RSI interpretation: Oversold (<30) - potential buy signal
- MACD signal: Bearish (-0.21) - potential sell signal
- Bollinger Bands position: Oversold (price touching lower band)
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines about the company's participation in a conference and the announcement of preliminary safety data from its trial.
Sentiment Assessment: Aggregate sentiment is POSITIVE, but it has had limited impact on the stock's price movement due to the overall market narrative being cautious.
Catalyst Identification: No significant catalysts identified in the short term. The company's participation in a conference and the announcement of preliminary safety data may have some impact in the medium term.
Risk & Volatility Assessment
Beta Interpretation: High risk profile (beta: 1.22) relative to the market.
Volatility Regime: Current volatility is high, but it is not unusual for this stock given its historical volatility levels.
Options Market Signals: IV rank: 23.4% (Low), put/call ratio: 0.00 (Bullish sentiment).
Market Context & Positioning
Sector Performance: OKUR is outperforming the sector in terms of relative strength, but it still has a high risk profile.
Institutional Activity: No significant institutional activity detected.
Correlation Analysis: Correlation with the market is 0.22, indicating some level of independence from the broader market trends.
Key Levels & Action Items
Critical Price Levels:
- Support: $3.14 (lower Bollinger Band)
- Resistance: $3.72 (SMA 20)
Breakout/Breakdown Levels: None identified in the short term.
Time-Sensitive Catalysts: No significant catalysts identified in the short term, but the company's participation in a conference and the announcement of preliminary safety data may have some impact in the medium term.
Risk Management: Stop-loss levels: $2.90, position sizing considerations: 50% to 70% allocation.
Overall, OKUR is experiencing high volatility, negative technical signals, and cautious market sentiment. While there are some positive news headlines, they do not seem to be enough to overcome the bearish trend.
Generated
News
All OKUR news →
Earnings History
3 of 3 under expected move
Avg Expected Move
109.66%
Avg Actual Move
2.44%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2025-05-06 | After-Close | 104.26% | 3.36% | 0.03x | Within |
| 2026-08-04 | After-Close | 119.51% | 1.46% | 0.01x | Within |
| 2026-11-04 | After-Close | 105.21% | 2.51% | 0.02x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
OKUR Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $1.82
7-DTE Move: $2.02
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 15
Put Volume: 6
P/C Volume: 0.4
BULLISH
Call OI: 17
Put OI: 153
P/C OI: 9.0
Total OI: 170
ATM Options Pricing
ATM Call: $1.70
ATM Put: $0.12
Call %: 54.5%
Put %: 4.0%
Chain Summary
Chain Volume: 21
Chain OI: 170
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$1.82Nov 9
Beta Analysis
Risk Metrics
Beta: 1.2990
Alpha: 16.79%
Correlation: 0.2510
R-Squared: 6.3%
Stock Volatility: 71.2%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own OKUR
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $5.4M | #2031 of 6285 | +3058.1% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $1.6M | #2077 of 3138 | -4.9% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
OKUR Institutional Ownership (13F)
Filings for 2026-06-30 · 12 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 22,647,640 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
1 filers$146 notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $146 | 100.00% | 2026-09-30 |
OKUR Insider Trading (Form 4)
Latest: 2026-09-23Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Nicholas A Saccomano | President and CEO | Sell (S) | −87 | $2.97 | -$259 | EDGAR |
| 2026-09-23 | Jason A. Leverone | Chief Financial Officer | Sell (S) | −302 | $2.97 | -$898 | EDGAR |
| 2026-08-13 | Isaac Manke | Director | — | — | — | EDGAR | |
| 2026-08-11 | Liam Ratcliffe | Director | Grant (A) | +22,350 opt | — | EDGAR | |
| 2026-08-11 | Michael G Grey | Director | Grant (A) | +22,350 opt | — | EDGAR | |
| 2026-08-11 | Andrew John Phillips | Director | Grant (A) | +22,350 opt | — | EDGAR | |
| 2026-08-11 | Isaac Manke | Director | Mixed | +300,000 opt | — | EDGAR | |
| 2026-08-11 | Samuel Agresta | Chief Medical Officer | Mixed | +50,000 opt | — | EDGAR | |
| 2026-08-11 | Edward T Mathers | Director | Grant (A) | +22,350 opt | — | EDGAR | |
| 2026-08-11 | Jason A. Leverone | Chief Financial Officer | Mixed | +50,000 opt | — | EDGAR | |
| 2026-08-11 | Dylan Hartley | Chief Scientific Officer | Mixed | +50,000 opt | — | EDGAR | |
| 2026-08-11 | Nicholas A Saccomano | President and CEO | Mixed | +150,000 opt | — | EDGAR | |
| 2026-08-11 | Valerie Malyvanh Jansen | Director | Grant (A) | +22,350 opt | — | EDGAR | |
| 2026-08-11 | R Michael Carruthers | Director | Grant (A) | +22,350 opt | — | EDGAR | |
| 2026-06-24 | Nicholas A Saccomano | President and CEO | Sell (S) | −86 | $4.40 | -$378 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
OKUR Insider Holdings
7 insiders · @ $3.19
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | ACORN CAPITAL ADVISORS GP, LLC | 10%+ Owner | 2,839,674 | $9.06M | $2.59M | 1 | 2025-05-19 |
| 2 | Cormorant Private Healthcare Fund IV LP | 10%+ Owner | 1,813,439 | $5.78M | -$48.2K | 1 | 2025-05-14 |
| 3 | Isaac Manke | Director | 20,583 | $65.7K | $0 | 8 | 2026-08-13 |
| 4 | Jason A. Leverone | Chief Financial Officer | 18,500 | $59.0K | -$15.1K | 11 | 2026-09-23 |
| 5 | Edward T Mathers | Director | 15,310 | $48.8K | $0 | 8 | 2026-08-11 |
| 6 | Nicholas A Saccomano | President and CEO | 11,160 | $35.6K | -$4.3K | 11 | 2026-09-23 |
| 7 | R Michael Carruthers | Director | 4,939 | $15.8K | $0 | 4 | 2026-08-11 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
OKUR Board & Officers
As of SEC filings through Sep 23, 2026Directors 6
- Andrew John Phillips · since Oct 4, 2024
- Isaac Manke · since Oct 4, 2024
- Nicholas A Saccomano · since Oct 4, 2024
- R Michael Carruthers · since Oct 4, 2024
- Valerie Malyvanh Jansen · since Oct 4, 2024
- Liam Ratcliffe · since Mar 31, 2026
Officers 4
- Nicholas A Saccomano · President and CEO · since Oct 4, 2024
- Jason A. Leverone · Chief Financial Officer · since Oct 4, 2024
- Dylan Hartley · Chief Scientific Officer · since Oct 4, 2024
- Samuel Agresta · Chief Medical Officer · since Oct 4, 2024
10% owners 9
- AI Biotechnology LLC (entity) · since Mar 31, 2026
- Access Industries Holdings LLC (entity) · since Mar 31, 2026
- Access Industries Management, LLC (entity) · since Mar 31, 2026
- Acorn Bioventures 2, L.p. (entity) · since May 15, 2025
- Acorn Bioventures, L.p. (entity) · since Oct 4, 2024
- Acorn Capital Advisors GP 2, LLC (entity) · since May 15, 2025
- Acorn Capital Advisors Gp, LLC (entity) · since Oct 4, 2024
- Anders D Hove · since Oct 4, 2024
- Len Blavatnik · since Mar 31, 2026
Changes in the last 10 years (77)
| Mar 31, 2026 | Liam Ratcliffe became a director |
| Mar 31, 2026 | Len Blavatnik became a 10% owner |
| Mar 31, 2026 | Access Industries Management, LLC became a 10% owner |
| Mar 31, 2026 | Access Industries Holdings LLC became a 10% owner |
| Mar 31, 2026 | AI Biotechnology LLC became a 10% owner |
| May 19, 2025 | Cormorant Private Healthcare Fund V LP reported in an SEC filing no longer being a 10% owner |
| May 19, 2025 | Cormorant Private Healthcare Fund IV LP reported in an SEC filing no longer being a 10% owner |
| May 19, 2025 | Cormorant Private Healthcare Fund III LP reported in an SEC filing no longer being a 10% owner |
| May 19, 2025 | Cormorant Global Healthcare Master Fund, LP reported in an SEC filing no longer being a 10% owner |
| May 19, 2025 | Cormorant Asset Management, LP reported in an SEC filing no longer being a 10% owner |
| May 19, 2025 | Bihua Chen reported in an SEC filing no longer being a 10% owner |
| May 15, 2025 | Acorn Capital Advisors GP 2, LLC became a 10% owner |
| May 15, 2025 | Acorn Bioventures 2, L.p. became a 10% owner |
| Oct 4, 2024 | Valerie Malyvanh Jansen became a director |
| Oct 4, 2024 | The company announced the departure of Michael G Grey from the board in an SEC filing |
| Oct 4, 2024 | The company announced the departure of Michael G Grey as Executive Chairman in an SEC filing |
| Oct 4, 2024 | The company announced the departure of Edward T Mathers from the board in an SEC filing |
| Oct 4, 2024 | Samuel Agresta became Chief Medical Officer |
| Oct 4, 2024 | R Michael Carruthers became a director |
| Oct 4, 2024 | Nicholas A Saccomano became a director |
| Oct 4, 2024 | Nicholas A Saccomano became President and CEO |
| Oct 4, 2024 | Jason A. Leverone became Chief Financial Officer |
| Oct 4, 2024 | Isaac Manke became a director |
| Oct 4, 2024 | Dylan Hartley became Chief Scientific Officer |
| Oct 4, 2024 | Cormorant Private Healthcare Fund V LP became a 10% owner |
| Oct 4, 2024 | Cormorant Private Healthcare Fund IV LP became a 10% owner |
| Oct 4, 2024 | Cormorant Private Healthcare Fund III LP became a 10% owner |
| Oct 4, 2024 | Cormorant Global Healthcare Master Fund, LP became a 10% owner |
| Oct 4, 2024 | Cormorant Asset Management, LP became a 10% owner |
| Oct 4, 2024 | Bihua Chen became a 10% owner |
| Oct 4, 2024 | Andrew John Phillips became a director |
| Oct 4, 2024 | Anders D Hove became a 10% owner |
| Oct 4, 2024 | Acorn Capital Advisors Gp, LLC became a 10% owner |
| Oct 4, 2024 | Acorn Bioventures, L.p. became a 10% owner |
| May 14, 2024 | Braden Michael Leonard became a 10% owner |
| Jun 23, 2023 | Novo Holdings A/S reported in an SEC filing no longer being a 10% owner |
| Aug 2, 2022 | Roshawn A. Blunt became a director |
| Mar 31, 2022 | Jennifer Lam became VP of Finance & Administration |
| Mar 4, 2022 | Michael Cruse listed as Chief Operating Officer (previously Senior VP-Corporate Operations) in SEC filings |
| Jan 28, 2022 | The company announced the departure of Vineet R. Jindal as Chief Financial Officer in an SEC filing |
| Jan 20, 2022 | The company announced the departure of Kenneth Ph.D. Harrison from the board in an SEC filing |
| Jan 20, 2022 | Paul W. Hoelscher became a director |
| Jan 18, 2022 | The company announced the departure of Lon Cardon from the board in an SEC filing |
| Aug 26, 2021 | Michael Cruse listed as Senior VP-Corporate Operations (previously Senior VP, Corporate Operation) in SEC filings |
| Apr 13, 2021 | RiverVest Venture Fund IV, L.P. reported in an SEC filing no longer being a 10% owner |
| Apr 13, 2021 | RiverVest Venture Fund III, L.P. reported in an SEC filing no longer being a 10% owner |
| Apr 13, 2021 | RiverVest Venture Fund III (Ohio), L.P. reported in an SEC filing no longer being a 10% owner |
| Apr 8, 2021 | Wendy S. Johnson became Chief Development Officer |
| Apr 8, 2021 | Vineet R. Jindal became Chief Financial Officer |
| Apr 8, 2021 | Stacey Denenberg Seltzer became a director |
| Apr 8, 2021 | Scott D Sandell became a 10% owner |
| Apr 8, 2021 | RiverVest Venture Fund IV, L.P. became a 10% owner |
| Apr 8, 2021 | RiverVest Venture Fund III, L.P. became a 10% owner |
| Apr 8, 2021 | RiverVest Venture Fund III (Ohio), L.P. became a 10% owner |
| Apr 8, 2021 | Peter W. Sonsini became a 10% owner |
| Apr 8, 2021 | Novo Holdings A/S became a 10% owner |
| Apr 8, 2021 | Niall O'Donnell became a director |
| Apr 8, 2021 | New Enterprise Associates 15, L.P. became a 10% owner |
| Apr 8, 2021 | Nea 15 Gp, LLC became a 10% owner |
| Apr 8, 2021 | NEA Partners 15, L.P. became a 10% owner |
| Apr 8, 2021 | Mohamad Makhzoumi became a 10% owner |
| Apr 8, 2021 | Michael G Grey became a director |
| Apr 8, 2021 | Michael G Grey became Executive Chairman |
| Apr 8, 2021 | Michael Cruse became Senior VP, Corporate Operation |
| Apr 8, 2021 | Lon Cardon became a director |
| Apr 8, 2021 | Kenneth Ph.D. Harrison became a director |
| Apr 8, 2021 | Joshua Makower became a 10% owner |
| Apr 8, 2021 | Johan Kordel became a director |
| Apr 8, 2021 | Gregory J. Flesher became a director |
| Apr 8, 2021 | Gregory J. Flesher became President and CEO |
| Apr 8, 2021 | Forest Baskett became a 10% owner |
| Apr 8, 2021 | Eric M Dube became a director |
| Apr 8, 2021 | Edward T Mathers became a director |
| Apr 8, 2021 | Bali Muralidhar became a director |
| Apr 8, 2021 | Anthony A. Florence Jr. became a 10% owner |
| Apr 8, 2021 | Alejandro Dorenbaum became Chief Medical Officer |
| Oct 11, 2020 | Ashley Hall became Chief Development Officer |
Not reported recently (23)
- Braden Michael Leonard · Last reported as a 10% owner in an SEC filing dated Sep 26, 2024
- Ashley Hall · Last reported as Chief Development Officer in an SEC filing dated Aug 29, 2023
- Stacey Denenberg Seltzer · Last reported as a director in an SEC filing dated Jun 8, 2023
- Niall O'Donnell · Last reported as a director in an SEC filing dated Jun 8, 2023
- Bali Muralidhar · Last reported as a director in an SEC filing dated Jun 8, 2023
- Eric M Dube · Last reported as a director in an SEC filing dated Jun 8, 2023
- Paul W. Hoelscher · Last reported as a director in an SEC filing dated Jun 8, 2023
- Roshawn A. Blunt · Last reported as a director in an SEC filing dated Jun 8, 2023
- Gregory J. Flesher · Last reported as a director in an SEC filing dated Dec 13, 2022
- Alejandro Dorenbaum · Last reported as Chief Medical Officer in an SEC filing dated Dec 13, 2022
- Michael Cruse · Last reported as Chief Operating Officer in an SEC filing dated Dec 13, 2022
- Jennifer Lam · Last reported as VP of Finance & Administration in an SEC filing dated Dec 13, 2022
- Wendy S. Johnson · Last reported as Chief Development Officer in an SEC filing dated Jul 15, 2021
- Anthony A. Florence Jr. · Last reported as a 10% owner in an SEC filing dated Apr 15, 2021
- NEA Partners 15, L.P. · Last reported as a 10% owner in an SEC filing dated Apr 15, 2021
- Scott D Sandell · Last reported as a 10% owner in an SEC filing dated Apr 15, 2021
- Mohamad Makhzoumi · Last reported as a 10% owner in an SEC filing dated Apr 15, 2021
- Peter W. Sonsini · Last reported as a 10% owner in an SEC filing dated Apr 15, 2021
- Joshua Makower · Last reported as a 10% owner in an SEC filing dated Apr 15, 2021
- Forest Baskett · Last reported as a 10% owner in an SEC filing dated Apr 15, 2021
- Nea 15 Gp, LLC · Last reported as a 10% owner in an SEC filing dated Apr 15, 2021
- New Enterprise Associates 15, L.P. · Last reported as a 10% owner in an SEC filing dated Apr 15, 2021
- Johan Kordel · Last reported as a director in an SEC filing dated Apr 8, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
OKUR Proposed Insider Sales (Form 144)
Latest: 2023-08-28
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2023-08-28 | Hall Ashley | Officer | 15,625 | $98.1K | 2023-08-28 | ETRADE FINANCIAL CORPORATION | — | EDGAR |
| 2023-06-23 | Novo Holdings A/S | 10% Stockholder | 100,000 | $735.0K | 2023-06-23 | Morgan Stanley & Co. LLC | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-04
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
20 ETFs hold OKUR
20 shown · $7.27M total exposure · 0.00% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $3.1M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.00% | $1.6M | $76.6B | 2026-11-06 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $833,101 | — | 2026-09-30 |
| 4 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.00% | $654,208 | $13.9B | 2026-11-06 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.00% | $412,500 | — | 2026-09-30 |
| 6 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.02% | $227,702 | $1.2B | 2026-11-06 |
| 7 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.00% | $88,963 | — | 2026-11-05 |
| 8 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.00% | $77,328 | $3.2B | 2026-11-05 |
| 9 | TMED T. Rowe Price Health Care ETF | Nport | 0.30% | $69,928 | — | 2026-06-30 |
| 10 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.00% | $65,599 | — | 2026-09-30 |
| 11 | RSSL Global X Russell 2000 ETF | Global X | 0.00% | $36,354 | — | 2026-11-06 |
| 12 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $9,396 | — | 2026-09-30 |
| 13 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.00% | $9,040 | — | 2026-11-05 |
| 14 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.00% | $4,243 | — | 2026-11-06 |
| 15 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $3,292 | — | 2026-11-06 |
| 16 | FSEV Fidelity Enhanced Small Cap Value ETF | Fidelity | 0.04% | $3,017 | $7.7M | 2026-11-05 |
| 17 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $2,249 | — | 2026-11-06 |
| 18 | AVTM Avantis Total Equity Markets ETF | Avantis | 0.00% | $1,273 | $742.8M | 2026-11-05 |
| 19 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $95 | — | 2026-11-06 |
| 20 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.00% | $23 | — | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-3.50
TTM Revenue
—
TTM Net Income
$-58.70M
TTM Op. Cash Flow
$-47.84M
Quarterly figures (7 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | — | $-15.35M | $-0.31 | $-10.35M |
| Q1 '26 | 2026-03-31 | — | $-15.16M | $-1.11 | $-12.94M |
| Q4 '25 | 2025-12-31 | — | $-13.50M | $-0.99 | $-11.51M |
| Q3 '25 | 2025-09-30 | — | $-14.70M | $-1.09 | $-13.04M |
| Q2 '25 | 2025-06-30 | — | $-15.39M | $-1.14 | $-13.27M |
| Q1 '25 | 2025-03-31 | — | $-15.93M | $-1.19 | $-14.01M |
| Q4 '24 | 2024-12-31 | — | $-17.44M | $96.49 | $-23.35M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-04
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.42
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-34.1%
ROA
-32.7%
Div Yield
0.00%
FCF Yield
-66.22%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$72.25M
as of 2026-11-09
OKUR vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 45.8 | +45.5% | +30.7% | 27 |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delawar | $353.2B | 30.0 | +9.7% | +18.2% | 40 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.2% | 47 |
| ISRG Intuitive Surgical Inc. | $160.0B | 55.7 | +20.5% | −18.0% | 12 |
| SYK Stryker Corporation | $124.1B | 34.7 | +7.9% | −6.4% | 34 |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.9B | 7.9 | +56.2% | −60.9% | 50 |
| PODD Insulet Corporation | $10.2B | 28.1 | +29.4% | −47.0% | 28 |
| DYN Dyne Therapeutics, Inc. Common Stock | $3.4B | — | — | +0.6% | 73 |
| OKUR OnKure Therapeutics, Inc. Class A Common | $118M | — | — | +7.8% | 21 |
| Peer median | $142.0B | 32.4 | +20.5% | −2.9% | 37 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
1.39M
SI % of Float
5.56%
Days to Cover
2.55
Short Vol Ratio
22.6%
Free Float
24.90M
Float %
61.7%
Short interest 2026-10-15 • Short volume 2026-11-09 • Float 2026-08-07